Actos Bladder Cancer and Injury
Texas Actos Bladder Cancer Attorney | Diabetes Drug Lawsuit | Actos Cancer Lawsuit | Actos damages | Actos Diabetes Drug Information | Dallas Actos Bladder Cancer Lawyer
Actos (pioglitazone) is an oral diabetes drug that was granted FDA approval in 1999 as a treatment for Type 2 diabetes to help reduce insulin resistance. While Actos is in the same class of drugs as Avandia, they are not the same and as medical studies revealed that Avandia use is responsible for heart disease, strokes, and other serious complications, use of Actos went up. Recent medical research, has demonstrated that Actos causes an increased risk of bladder cancer in users, and that this risk increases the longer the medication is taken.
Our experienced product liability attorneys are holding Takeda Pharmaceuticals accountable by filing Actos lawsuits on behalf of those victims who have been diagnosed with bladder cancer after being prescribed this Type 2 diabetes medication. Our Actos lawyers represent every Actos bladder cancer lawsuit client on a contingent fee basis, meaning there are never any legal fees or costs unless we win your case.
A month after French regulators suspended sales of their popular diabetes drug due to concerns about an increased risk of bladder cancer, Takeda Pharmaceuticals has agreed to issue an Actos recall in France. Currently, there is no indication that the drug maker is going to voluntarily take similar action in the United States.
Actos (pioglitazone) was approved in the U.S. in July 1999, for treatment of type 2 diabetes. The medication is Takeda Pharmaceuticals’ best-selling drug, with sales of $3.4 billion last year. In June, regulators in France and Germany announced that sales of the drug were being suspended due to a potential risk of bladder cancer from Actos.
Takeda Pharmaceuticals has now agreed to recall Actos in France after being pressured by Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). The related drug Campetact, which is sold as Actoplus Met in the United States, will also be recalled in France.
The potential bladder cancer side effects of Actos are still being reviewed by regulators in the rest of the European Union, Canada and by the FDA in the United States, after studies have shown an increased risk of bladder cancer with Actos
In June, the FDA announced that new Actos bladder cancer warnings will be added to the drug’s label, alerting users about the potential increased risk if the drug is used for more than one year. All drugs containing pioglitazone, the active ingredient in Actos, will carry the new warning, including Actoplus Met, ActoplusMet RX and Duetact. The FDA is continuing to weigh the potential risk of bladder cancer from Actos against the benefits provided by the medication.
Quick Facts: Actos Bladder Cancer Risks
In 2007, the FDA issued a "black box" warning that included both Actos and Avandia. One five-year study involving 193,099 patients showed that people who took Actos for 12 months or longer had a 40% increase in their risk of developing bladder cancer. An adverse event report study later conducted showed that one-fifth of all reports of diagnoses of bladder cancer in diabetes drug users involved Actos.
In June of 2011, the FDA issued stronger warnings – mentioning the risk of bladder cancer specifically – against use of the drug. However, even with the severity of the warnings, Actos is still being prescribed and taken today.
The FDA first announced that there may be a possible connection between bladder cancer and Actos in September 2010, after preliminary data from an on-going 10 year study suggested that there may be an increased risk the longer the drug is taken.
In May 2011, a study by Italian researchers found a disproportionate number of Actos bladder cancer reports in the FDA’s own Adverse Event Reporting System Records. However, that study did not establish a causal effect between Actos and bladder cancer. Concerns about an Actos bladder cancer risk increased even further last month, after a review of insurance data on 1.5 million French citizens identified an increased occurrence of bladder cancer among Actos users.
Read the JAMA Article here.
Throughout the United States, a number of patients who took Actos, and now diagnosed with bladder cancer are considering filing potential lawsuits against Takeda Pharmaceuticals for failing to fully research the side effects of the medication or adequately warn about the risk of bladder cancer.
Our law firm’s principal office is in Southlake and we have offices in Fort Worth and in Dallas, Texas. Dr Shezad Malik Law Firm represents clients in dangerous drug and dangerous medical device lawsuits nationwide, including | Alabama | Alaska | Arizona | Arkansas | California | Colorado | Connecticut | Delaware | Florida | Georgia | Hawaii | Idaho | Illinois | Indiana | Iowa | Kansas | Kentucky | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Ohio | Oklahoma | Oregon | Pennsylvania | Rhode Island | South Carolina | South Dakota | Tennessee | Texas | Utah | Vermont | Virginia | Washington | West Virginia | Wisconsin | Wyoming
We also serve the cities of | New York | Los Angeles | Chicago | Houston | Phoenix | Philadelphia | San Antonio | San Diego | Dallas | San Jose City | Detroit | Jacksonville | Indianapolis | San Francisco | Columbus | Austin | Memphis | Fort Worth | Baltimore | Charlotte | Boston | Seattle | Washington | Milwaukee | Denver | Louisville | Las Vegas | Nashville | Oklahoma City | Portland | Tucson | Albuquerque | Atlanta | Long Beach | Fresno | Sacramento | Mesa | Kansas City | Cleveland | Virginia Beach | Omaha | Miam | Oakland | Tulsa | Honolulu | Minneapolis | Colorado Springs | Arlington | Wichita
Actos (pioglitazone) is an oral diabetes drug that was granted FDA approval in 1999 as a treatment for Type 2 diabetes to help reduce insulin resistance. While Actos is in the same class of drugs as Avandia, they are not the same and as medical studies revealed that Avandia use is responsible for heart disease, strokes, and other serious complications, use of Actos went up. Recent medical research, has demonstrated that Actos causes an increased risk of bladder cancer in users, and that this risk increases the longer the medication is taken.
Our experienced product liability attorneys are holding Takeda Pharmaceuticals accountable by filing Actos lawsuits on behalf of those victims who have been diagnosed with bladder cancer after being prescribed this Type 2 diabetes medication. Our Actos lawyers represent every Actos bladder cancer lawsuit client on a contingent fee basis, meaning there are never any legal fees or costs unless we win your case.
A month after French regulators suspended sales of their popular diabetes drug due to concerns about an increased risk of bladder cancer, Takeda Pharmaceuticals has agreed to issue an Actos recall in France. Currently, there is no indication that the drug maker is going to voluntarily take similar action in the United States.
Actos (pioglitazone) was approved in the U.S. in July 1999, for treatment of type 2 diabetes. The medication is Takeda Pharmaceuticals’ best-selling drug, with sales of $3.4 billion last year. In June, regulators in France and Germany announced that sales of the drug were being suspended due to a potential risk of bladder cancer from Actos.
Takeda Pharmaceuticals has now agreed to recall Actos in France after being pressured by Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). The related drug Campetact, which is sold as Actoplus Met in the United States, will also be recalled in France.
The potential bladder cancer side effects of Actos are still being reviewed by regulators in the rest of the European Union, Canada and by the FDA in the United States, after studies have shown an increased risk of bladder cancer with Actos
In June, the FDA announced that new Actos bladder cancer warnings will be added to the drug’s label, alerting users about the potential increased risk if the drug is used for more than one year. All drugs containing pioglitazone, the active ingredient in Actos, will carry the new warning, including Actoplus Met, ActoplusMet RX and Duetact. The FDA is continuing to weigh the potential risk of bladder cancer from Actos against the benefits provided by the medication.
Quick Facts: Actos Bladder Cancer Risks
In 2007, the FDA issued a "black box" warning that included both Actos and Avandia. One five-year study involving 193,099 patients showed that people who took Actos for 12 months or longer had a 40% increase in their risk of developing bladder cancer. An adverse event report study later conducted showed that one-fifth of all reports of diagnoses of bladder cancer in diabetes drug users involved Actos.
In June of 2011, the FDA issued stronger warnings – mentioning the risk of bladder cancer specifically – against use of the drug. However, even with the severity of the warnings, Actos is still being prescribed and taken today.
The FDA first announced that there may be a possible connection between bladder cancer and Actos in September 2010, after preliminary data from an on-going 10 year study suggested that there may be an increased risk the longer the drug is taken.
In May 2011, a study by Italian researchers found a disproportionate number of Actos bladder cancer reports in the FDA’s own Adverse Event Reporting System Records. However, that study did not establish a causal effect between Actos and bladder cancer. Concerns about an Actos bladder cancer risk increased even further last month, after a review of insurance data on 1.5 million French citizens identified an increased occurrence of bladder cancer among Actos users.
Read the JAMA Article here.
Throughout the United States, a number of patients who took Actos, and now diagnosed with bladder cancer are considering filing potential lawsuits against Takeda Pharmaceuticals for failing to fully research the side effects of the medication or adequately warn about the risk of bladder cancer.
Our law firm’s principal office is in Southlake and we have offices in Fort Worth and in Dallas, Texas. Dr Shezad Malik Law Firm represents clients in dangerous drug and dangerous medical device lawsuits nationwide, including | Alabama | Alaska | Arizona | Arkansas | California | Colorado | Connecticut | Delaware | Florida | Georgia | Hawaii | Idaho | Illinois | Indiana | Iowa | Kansas | Kentucky | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Ohio | Oklahoma | Oregon | Pennsylvania | Rhode Island | South Carolina | South Dakota | Tennessee | Texas | Utah | Vermont | Virginia | Washington | West Virginia | Wisconsin | Wyoming
We also serve the cities of | New York | Los Angeles | Chicago | Houston | Phoenix | Philadelphia | San Antonio | San Diego | Dallas | San Jose City | Detroit | Jacksonville | Indianapolis | San Francisco | Columbus | Austin | Memphis | Fort Worth | Baltimore | Charlotte | Boston | Seattle | Washington | Milwaukee | Denver | Louisville | Las Vegas | Nashville | Oklahoma City | Portland | Tucson | Albuquerque | Atlanta | Long Beach | Fresno | Sacramento | Mesa | Kansas City | Cleveland | Virginia Beach | Omaha | Miam | Oakland | Tulsa | Honolulu | Minneapolis | Colorado Springs | Arlington | Wichita